首页 > 最新文献

Expert Review of Proteomics最新文献

英文 中文
Advances in the clinical use of metaproteomics. 元蛋白质组学的临床应用进展。
IF 3.4 3区 生物学 Q1 BIOCHEMICAL RESEARCH METHODS Pub Date : 2023-04-01 DOI: 10.1080/14789450.2023.2215440
Maximilian Wolf, Kay Schallert, Luca Knipper, Albert Sickmann, Alexander Sczyrba, Dirk Benndorf, Robert Heyer

Introduction: Investigating the taxonomic and functional composition of human microbiomes can aid in the understanding of disease etiologies, diagnosis, and therapy monitoring for several diseases, including inflammatory bowel disease or obesity. One method for microbiome monitoring is metaproteomics, which assesses human and microbial proteins and thus enables the study of host-microbiome interactions. This advantage led to increased interest in metaproteome analyses and significant developments to introduce this method into a clinical context.

Areas covered: This review summarizes the recent progress from a technical side and an application-related point of view.

Expert opinion: Numerous publications imply the massive potential of metaproteomics to impact human health care. However, the key challenges of standardization and validation of experimental and bioinformatic workflows and accurate quantification methods must be overcome.

研究人类微生物组的分类和功能组成有助于了解疾病的病因、诊断和几种疾病的治疗监测,包括炎症性肠病或肥胖症。微生物组监测的一种方法是元蛋白质组学,它评估人类和微生物蛋白质,从而能够研究宿主-微生物组的相互作用。这一优势增加了对元蛋白质组分析的兴趣,并将该方法引入临床环境。涵盖的领域:本综述从技术方面和应用相关的角度总结了最近的进展。专家意见:许多出版物暗示了元蛋白质组学影响人类健康保健的巨大潜力。然而,必须克服标准化和验证实验和生物信息学工作流程以及准确量化方法的关键挑战。
{"title":"Advances in the clinical use of metaproteomics.","authors":"Maximilian Wolf,&nbsp;Kay Schallert,&nbsp;Luca Knipper,&nbsp;Albert Sickmann,&nbsp;Alexander Sczyrba,&nbsp;Dirk Benndorf,&nbsp;Robert Heyer","doi":"10.1080/14789450.2023.2215440","DOIUrl":"https://doi.org/10.1080/14789450.2023.2215440","url":null,"abstract":"<p><strong>Introduction: </strong>Investigating the taxonomic and functional composition of human microbiomes can aid in the understanding of disease etiologies, diagnosis, and therapy monitoring for several diseases, including inflammatory bowel disease or obesity. One method for microbiome monitoring is metaproteomics, which assesses human and microbial proteins and thus enables the study of host-microbiome interactions. This advantage led to increased interest in metaproteome analyses and significant developments to introduce this method into a clinical context.</p><p><strong>Areas covered: </strong>This review summarizes the recent progress from a technical side and an application-related point of view.</p><p><strong>Expert opinion: </strong>Numerous publications imply the massive potential of metaproteomics to impact human health care. However, the key challenges of standardization and validation of experimental and bioinformatic workflows and accurate quantification methods must be overcome.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"20 4-6","pages":"71-86"},"PeriodicalIF":3.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9740800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Data-independent acquisition mass spectrometry reveals comprehensive plasma protein profiles in the natural history of patients with hereditary transthyretin amyloidosis (ATTRv). 数据独立采集质谱揭示了遗传性甲状腺转蛋白淀粉样变性(ATTRv)患者自然史中的全面血浆蛋白谱。
IF 3.4 3区 生物学 Q1 BIOCHEMICAL RESEARCH METHODS Pub Date : 2023-01-01 DOI: 10.1080/14789450.2023.2195096
Shan He, XinYue He, RuoKai Pan, LuRong Pan, Xiaoying Lv, YuTong Jin, Yue Fan, YuTong Wang, Zhuang Tian, ShuYang Zhang

Objectives: Hereditary transthyretin amyloidosis (ATTRv) is a rare, fatal, autosomal dominant disease with more than 140 mutations discovered. Three phenotypes of amyloid infiltration are neuropathy (ATTRv-PN), cardiopathy (ATTRv-CM), and neuropathy + cardiopathy (ATTRv-MIX). The lack of ATTR-specific biomarkers, difficulties in biopsy evidence, and limited known pathogenic mechanisms have made diagnosis difficult. Newly emerging noninvasive measures for monitoring progression and disease-modifying therapies have improved early diagnosis and patient management.

Methods: Our research applies the latest technology, Data-Independent Acquisition-Based Quantitative Proteomics (DIA), to reveal comprehensive plasma protein profiles in the natural history of Chinese patients with hereditary transthyretin amyloidosis (ATTRv). We analyzed differentially expressed proteins (DEPs) in three phenotypes (ATTRv-PN, ATTRv-CM, and ATTRv-MIX).

Results: Serum samples were collected from a total of 18 patients (6 ATTRv-PN, 5 ATTRv-CM, and 7 ATTRv-MIX patients) and 20 healthy participants as a control group. Combined with the results of the proteomic and bioinformatic analyses, we found 30 DEPs and protein interaction networks clustered in KRT family proteins and DSC3 between ATTRv-PN and the control, which were rich in the estrogen signaling pathway and the cell adhesion molecule (CAM) pathway.

Conclusion: This study demonstrates a global and significant proteomic profile in different stages of ATTRv.

目的:遗传性甲状腺转蛋白淀粉样变性(ATTRv)是一种罕见的、致命的常染色体显性遗传病,发现有140多种突变。淀粉样蛋白浸润的三种表型是神经病(ATTRv-PN)、心脏病(ATTRv-CM)和神经病+心脏病(ATTRv-MIX)。缺乏atr特异性生物标志物,活检证据困难,已知的致病机制有限,使得诊断困难。新出现的监测进展和疾病改善治疗的无创措施改善了早期诊断和患者管理。方法:本研究采用最新的基于数据独立获取的定量蛋白质组学(DIA)技术,揭示中国遗传性甲状腺转蛋白淀粉样变性(ATTRv)患者的全面血浆蛋白谱。我们分析了三种表型(ATTRv-PN、ATTRv-CM和ATTRv-MIX)的差异表达蛋白(DEPs)。结果:共收集了18例患者(6例ATTRv-PN患者,5例ATTRv-CM患者,7例ATTRv-MIX患者)的血清样本,20例健康参与者作为对照组。结合蛋白组学和生物信息学分析结果,我们发现ATTRv-PN与对照之间聚集在KRT家族蛋白和DSC3中30个DEPs和蛋白相互作用网络,这些网络富含雌激素信号通路和细胞粘附分子(CAM)通路。结论:本研究显示了atv不同阶段的全局和显著的蛋白质组学特征。
{"title":"Data-independent acquisition mass spectrometry reveals comprehensive plasma protein profiles in the natural history of patients with hereditary transthyretin amyloidosis (ATTRv).","authors":"Shan He,&nbsp;XinYue He,&nbsp;RuoKai Pan,&nbsp;LuRong Pan,&nbsp;Xiaoying Lv,&nbsp;YuTong Jin,&nbsp;Yue Fan,&nbsp;YuTong Wang,&nbsp;Zhuang Tian,&nbsp;ShuYang Zhang","doi":"10.1080/14789450.2023.2195096","DOIUrl":"https://doi.org/10.1080/14789450.2023.2195096","url":null,"abstract":"<p><strong>Objectives: </strong>Hereditary transthyretin amyloidosis (ATTRv) is a rare, fatal, autosomal dominant disease with more than 140 mutations discovered. Three phenotypes of amyloid infiltration are neuropathy (ATTRv-PN), cardiopathy (ATTRv-CM), and neuropathy + cardiopathy (ATTRv-MIX). The lack of ATTR-specific biomarkers, difficulties in biopsy evidence, and limited known pathogenic mechanisms have made diagnosis difficult. Newly emerging noninvasive measures for monitoring progression and disease-modifying therapies have improved early diagnosis and patient management.</p><p><strong>Methods: </strong>Our research applies the latest technology, Data-Independent Acquisition-Based Quantitative Proteomics (DIA), to reveal comprehensive plasma protein profiles in the natural history of Chinese patients with hereditary transthyretin amyloidosis (ATTRv). We analyzed differentially expressed proteins (DEPs) in three phenotypes (ATTRv-PN, ATTRv-CM, and ATTRv-MIX).</p><p><strong>Results: </strong>Serum samples were collected from a total of 18 patients (6 ATTRv-PN, 5 ATTRv-CM, and 7 ATTRv-MIX patients) and 20 healthy participants as a control group. Combined with the results of the proteomic and bioinformatic analyses, we found 30 DEPs and protein interaction networks clustered in KRT family proteins and DSC3 between ATTRv-PN and the control, which were rich in the estrogen signaling pathway and the cell adhesion molecule (CAM) pathway.</p><p><strong>Conclusion: </strong>This study demonstrates a global and significant proteomic profile in different stages of ATTRv.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"20 1-3","pages":"57-69"},"PeriodicalIF":3.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9536233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LC-MS/MS: A sensitive and selective analytical technique to detect COVID-19 protein biomarkers in the early disease stage. LC-MS/MS:一种在疾病早期检测COVID-19蛋白生物标志物的灵敏和选择性分析技术。
IF 3.4 3区 生物学 Q1 BIOCHEMICAL RESEARCH METHODS Pub Date : 2023-01-01 DOI: 10.1080/14789450.2023.2191845
Siva Nageswara Rao Gajula, Ankita Sahebrao Khairnar, Pallavi Jock, Nikita Kumari, Kendre Pratima, Vijay Munjal, Pavan Kalan, Rajesh Sonti

Introduction: The COVID-19 outbreak has put enormous pressure on the scientific community to detect infection rapidly, identify the status of disease severity, and provide an immediate vaccine/drug for the treatment. Relying on immunoassay and a real-time reverse transcription polymerase chain reaction (rRT-PCR) led to many false-negative and false-positive reports. Therefore, detecting biomarkers is an alternative and reliable approach for determining the infection, its severity, and disease progression. Recent advances in liquid chromatography and mass spectrometry (LC-MS/MS) enable the protein biomarkers even at low concentrations, thus facilitating clinicians to monitor the treatment in hospitals.

Areas covered: This review highlights the role of LC-MS/MS in identifying protein biomarkers and discusses the clinically significant protein biomarkers such as Serum amyloid A, Interleukin-6, C-Reactive Protein, Lactate dehydrogenase, D-dimer, cardiac troponin, ferritin, Alanine transaminase, Aspartate transaminase, gelsolin and galectin-3-binding protein in COVID-19, and their analysis by LC-MS/MS in the early stage.

Expert opinion: Clinical doctors monitor significant biomarkers to understand, stratify, and treat patients according to disease severity. Knowledge of clinically significant COVID-19 protein biomarkers is critical not only for COVID-19 caused by the coronavirus but also to prepare us for future pandemics of other diseases in detecting by LC-MS/MS at the early stages.

2019冠状病毒病疫情给科学界带来了巨大压力,需要迅速发现感染,确定疾病严重程度,并立即提供用于治疗的疫苗/药物。依靠免疫测定和实时逆转录聚合酶链反应(rRT-PCR)导致许多假阴性和假阳性报告。因此,检测生物标志物是确定感染、严重程度和疾病进展的一种可靠的替代方法。液相色谱和质谱分析(LC-MS/MS)的最新进展使蛋白质生物标志物即使在低浓度下也能检测到,从而便于临床医生监测医院的治疗情况。本综述重点介绍了LC-MS/MS在鉴定蛋白质生物标志物方面的作用,并讨论了COVID-19中具有临床意义的蛋白质生物标志物,如血清淀粉样蛋白A、白细胞介素-6、c反应蛋白、乳酸脱氢酶、d -二聚体、心脏肌钙蛋白、铁蛋白、丙氨酸转氨酶、天冬氨酸转氨酶、凝胶蛋白和半乳糖凝集素-3结合蛋白,以及它们在早期的LC-MS/MS分析。专家意见:临床医生监测重要的生物标志物,以根据疾病严重程度了解、分层和治疗患者。了解具有临床意义的COVID-19蛋白生物标志物不仅对新冠病毒引起的COVID-19至关重要,而且对我们在LC-MS/MS早期检测其他疾病的未来大流行也至关重要。
{"title":"LC-MS/MS: A sensitive and selective analytical technique to detect COVID-19 protein biomarkers in the early disease stage.","authors":"Siva Nageswara Rao Gajula,&nbsp;Ankita Sahebrao Khairnar,&nbsp;Pallavi Jock,&nbsp;Nikita Kumari,&nbsp;Kendre Pratima,&nbsp;Vijay Munjal,&nbsp;Pavan Kalan,&nbsp;Rajesh Sonti","doi":"10.1080/14789450.2023.2191845","DOIUrl":"https://doi.org/10.1080/14789450.2023.2191845","url":null,"abstract":"<p><strong>Introduction: </strong>The COVID-19 outbreak has put enormous pressure on the scientific community to detect infection rapidly, identify the status of disease severity, and provide an immediate vaccine/drug for the treatment. Relying on immunoassay and a real-time reverse transcription polymerase chain reaction (rRT-PCR) led to many false-negative and false-positive reports. Therefore, detecting biomarkers is an alternative and reliable approach for determining the infection, its severity, and disease progression. Recent advances in liquid chromatography and mass spectrometry (LC-MS/MS) enable the protein biomarkers even at low concentrations, thus facilitating clinicians to monitor the treatment in hospitals.</p><p><strong>Areas covered: </strong>This review highlights the role of LC-MS/MS in identifying protein biomarkers and discusses the clinically significant protein biomarkers such as Serum amyloid A, Interleukin-6, C-Reactive Protein, Lactate dehydrogenase, D-dimer, cardiac troponin, ferritin, Alanine transaminase, Aspartate transaminase, gelsolin and galectin-3-binding protein in COVID-19, and their analysis by LC-MS/MS in the early stage.</p><p><strong>Expert opinion: </strong>Clinical doctors monitor significant biomarkers to understand, stratify, and treat patients according to disease severity. Knowledge of clinically significant COVID-19 protein biomarkers is critical not only for COVID-19 caused by the coronavirus but also to prepare us for future pandemics of other diseases in detecting by LC-MS/MS at the early stages.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"20 1-3","pages":"5-18"},"PeriodicalIF":3.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9831802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Mapping the human sperm proteome - novel insights into reproductive research. 绘制人类精子蛋白质组图——生殖研究的新见解。
IF 3.4 3区 生物学 Q1 BIOCHEMICAL RESEARCH METHODS Pub Date : 2023-01-01 DOI: 10.1080/14789450.2023.2210764
Mika Alexia Miyazaki, Raquel Lozano Guilharducci, Paula Intasqui, Ricardo Pimenta Bertolla

Introduction: Spermatozoa are highly specialized cells with unique morphology. In addition, spermatozoa lose a considerable amount of cytoplasm during spermiogenesis, when they also compact their DNA, resulting in a transcriptionally quiescent cell. Throughout the male reproductive tract, sperm will acquire proteins that enable them to interact with the female reproductive tract. After ejaculation, proteins undergo post-translational modifications for sperm to capacitate, hyperactivate, and fertilize the oocyte. Many proteins have been identified as predictors of male infertility and also investigated in diseases that compromise reproductive potential.

Areas covered: In this review, we proposed to summarize the recent findings about the sperm proteome and how they affect sperm structure, function, and fertility. A literature search was performed using PubMed and Google Scholar databases within the past 5 years until August 2022.

Expert opinion: Sperm function depends on protein abundance, conformation, and PTMs; understanding the sperm proteome may help to identify pathways essential to fertility, even making it possible to unravel the mechanisms involved in idiopathic infertility. In addition, proteomics evaluation offers knowledge regarding alterations that compromise the male reproductive potential.

精子是高度特化的细胞,具有独特的形态。此外,在精子发生过程中,精子失去了相当数量的细胞质,同时它们也压缩了它们的DNA,导致转录静止细胞。在整个男性生殖道中,精子会获得蛋白质,使它们能够与女性生殖道相互作用。射精后,蛋白质经过翻译后的修饰,使精子能化、超激活并使卵母细胞受精。许多蛋白质已被确定为男性不育的预测因子,并在损害生殖潜力的疾病中进行了研究。涉及领域:本文就精子蛋白质组及其对精子结构、功能和生育能力的影响等方面的研究进展进行综述。使用PubMed和Google Scholar数据库进行文献检索,检索时间为过去5年至2022年8月。专家意见:精子功能取决于蛋白质丰度、构象和PTMs;了解精子蛋白质组可能有助于确定对生育至关重要的途径,甚至使揭示特发性不孕症的机制成为可能。此外,蛋白质组学评估提供了有关损害男性生殖潜力的改变的知识。
{"title":"Mapping the human sperm proteome - novel insights into reproductive research.","authors":"Mika Alexia Miyazaki,&nbsp;Raquel Lozano Guilharducci,&nbsp;Paula Intasqui,&nbsp;Ricardo Pimenta Bertolla","doi":"10.1080/14789450.2023.2210764","DOIUrl":"https://doi.org/10.1080/14789450.2023.2210764","url":null,"abstract":"<p><strong>Introduction: </strong>Spermatozoa are highly specialized cells with unique morphology. In addition, spermatozoa lose a considerable amount of cytoplasm during spermiogenesis, when they also compact their DNA, resulting in a transcriptionally quiescent cell. Throughout the male reproductive tract, sperm will acquire proteins that enable them to interact with the female reproductive tract. After ejaculation, proteins undergo post-translational modifications for sperm to capacitate, hyperactivate, and fertilize the oocyte. Many proteins have been identified as predictors of male infertility and also investigated in diseases that compromise reproductive potential.</p><p><strong>Areas covered: </strong>In this review, we proposed to summarize the recent findings about the sperm proteome and how they affect sperm structure, function, and fertility. A literature search was performed using PubMed and Google Scholar databases within the past 5 years until August 2022.</p><p><strong>Expert opinion: </strong>Sperm function depends on protein abundance, conformation, and PTMs; understanding the sperm proteome may help to identify pathways essential to fertility, even making it possible to unravel the mechanisms involved in idiopathic infertility. In addition, proteomics evaluation offers knowledge regarding alterations that compromise the male reproductive potential.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"20 1-3","pages":"19-45"},"PeriodicalIF":3.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
How valuable can proteogenomics be in clinical breast cancer research? 蛋白质基因组学在临床乳腺癌研究中的价值有多大?
IF 3.4 3区 生物学 Q1 BIOCHEMICAL RESEARCH METHODS Pub Date : 2023-01-01 DOI: 10.1080/14789450.2023.2203390
Anh M Tran-Huynh, Matthew V Holt, Meenakshi Anurag
Nearly, 45,000 women are estimated to die from breast cancer in 2022 in the US alone [1,2]. Breast cancer displays high heterogeneity with a wide spectrum of clinical, pathological, and molecular features, which makes it challenging for successful therapy. As we are inching toward the era of personalized medicine, advances in subtyping breast tumors have impacted prognosis and therapeutics [3]. Proteogenomics, which is an integrative profiling approach utilizing DNA, RNA, and protein data, has clearly played a critical role in illuminating the complexity of breast tumor biology, and predicting treatment response. Since DNA and RNA sequencing has gained momentum in breast cancer clinical assays including targeted mutation panel or RNA-based PAM50-based intrinsic subtyping, it is important to highlight the capabilities of integrative approaches rather than focusing on proteomics in silo. The complementation of proteomics platform provides an opportunity not just for biomarker assessment but also better quantification of targetable proteins and pathways. This methodological advancement provides an elaborate molecular landscape of breast tumors in light of treatment response and toxicity [4,5].
{"title":"How valuable can proteogenomics be in clinical breast cancer research?","authors":"Anh M Tran-Huynh,&nbsp;Matthew V Holt,&nbsp;Meenakshi Anurag","doi":"10.1080/14789450.2023.2203390","DOIUrl":"https://doi.org/10.1080/14789450.2023.2203390","url":null,"abstract":"Nearly, 45,000 women are estimated to die from breast cancer in 2022 in the US alone [1,2]. Breast cancer displays high heterogeneity with a wide spectrum of clinical, pathological, and molecular features, which makes it challenging for successful therapy. As we are inching toward the era of personalized medicine, advances in subtyping breast tumors have impacted prognosis and therapeutics [3]. Proteogenomics, which is an integrative profiling approach utilizing DNA, RNA, and protein data, has clearly played a critical role in illuminating the complexity of breast tumor biology, and predicting treatment response. Since DNA and RNA sequencing has gained momentum in breast cancer clinical assays including targeted mutation panel or RNA-based PAM50-based intrinsic subtyping, it is important to highlight the capabilities of integrative approaches rather than focusing on proteomics in silo. The complementation of proteomics platform provides an opportunity not just for biomarker assessment but also better quantification of targetable proteins and pathways. This methodological advancement provides an elaborate molecular landscape of breast tumors in light of treatment response and toxicity [4,5].","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"20 1-3","pages":"1-4"},"PeriodicalIF":3.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9849746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updates on the study of lysosomal protein dynamics: possibilities for the clinic. 溶酶体蛋白动力学研究的最新进展:临床应用的可能性。
IF 3.4 3区 生物学 Q1 BIOCHEMICAL RESEARCH METHODS Pub Date : 2023-01-01 DOI: 10.1080/14789450.2023.2190515
Dhriti Arora, Yannic Hackenberg, Jiaran Li, Dominic Winter

Introduction: The lysosome is the main degradative organelle of almost all mammalian cells, fulfilling important functions in macromolecule recycling, metabolism, and signaling. Lysosomal dysfunction is connected to a continuously growing number of pathologic conditions, and lysosomal proteins present potential biomarkers for a variety of diseases. Therefore, there is an increasing interest in their analysis in patient samples.

Areas covered: We provide an overview of OMICs studies which identified lysosomal proteins as potential biomarkers for pathological conditions, covering proteomics, genomics, and transcriptomics approaches, identified through PubMed searches. With respect to discovery proteomics analyses, mainly lysosomal luminal and associated proteins were detected, while membrane proteins were found less frequently. Comprehensive coverage of the lysosomal proteome was only achieved by ultra-deep-coverage studies, but targeted approaches allowed for the reproducible quantification of lysosomal proteins in diverse sample types.

Expert opinion: The low abundance of lysosomal proteins complicates their reproducible analysis in patient samples. Whole proteome shotgun analyses fail in many instances to cover the lysosomal proteome, which is due to under-sampling and/or a lack of sensitivity. With the current state of the art, targeted proteomics assays provide the best performance for the characterization of lysosomal proteins in patient samples.

溶酶体是几乎所有哺乳动物细胞的主要降解细胞器,在大分子循环、代谢和信号传导等方面发挥着重要作用。溶酶体功能障碍与不断增长的病理状况有关,溶酶体蛋白是多种疾病的潜在生物标志物。因此,人们对他们在患者样本中的分析越来越感兴趣。涵盖领域:我们提供了组学研究的概述,这些研究确定了溶酶体蛋白作为病理条件的潜在生物标志物,涵盖蛋白质组学,基因组学和转录组学方法,通过PubMed搜索确定。发现蛋白组学分析以溶酶体管腔蛋白和相关蛋白为主,膜蛋白较少。对溶酶体蛋白质组的全面覆盖只有通过超深度覆盖研究才能实现,但靶向方法允许在不同样品类型中对溶酶体蛋白进行可重复的定量。专家意见:溶酶体蛋白的低丰度使其在患者样本中的可重复性分析复杂化。全蛋白质组霰弹枪分析在许多情况下无法覆盖溶酶体蛋白质组,这是由于采样不足和/或缺乏灵敏度。随着目前技术的发展,靶向蛋白质组学分析为患者样品中溶酶体蛋白的表征提供了最佳性能。
{"title":"Updates on the study of lysosomal protein dynamics: possibilities for the clinic.","authors":"Dhriti Arora,&nbsp;Yannic Hackenberg,&nbsp;Jiaran Li,&nbsp;Dominic Winter","doi":"10.1080/14789450.2023.2190515","DOIUrl":"https://doi.org/10.1080/14789450.2023.2190515","url":null,"abstract":"<p><strong>Introduction: </strong>The lysosome is the main degradative organelle of almost all mammalian cells, fulfilling important functions in macromolecule recycling, metabolism, and signaling. Lysosomal dysfunction is connected to a continuously growing number of pathologic conditions, and lysosomal proteins present potential biomarkers for a variety of diseases. Therefore, there is an increasing interest in their analysis in patient samples.</p><p><strong>Areas covered: </strong>We provide an overview of OMICs studies which identified lysosomal proteins as potential biomarkers for pathological conditions, covering proteomics, genomics, and transcriptomics approaches, identified through PubMed searches. With respect to discovery proteomics analyses, mainly lysosomal luminal and associated proteins were detected, while membrane proteins were found less frequently. Comprehensive coverage of the lysosomal proteome was only achieved by ultra-deep-coverage studies, but targeted approaches allowed for the reproducible quantification of lysosomal proteins in diverse sample types.</p><p><strong>Expert opinion: </strong>The low abundance of lysosomal proteins complicates their reproducible analysis in patient samples. Whole proteome shotgun analyses fail in many instances to cover the lysosomal proteome, which is due to under-sampling and/or a lack of sensitivity. With the current state of the art, targeted proteomics assays provide the best performance for the characterization of lysosomal proteins in patient samples.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"20 1-3","pages":"47-55"},"PeriodicalIF":3.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9831804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proteomic repository data submission, dissemination, and reuse: key messages. 蛋白质组资源库数据的提交、传播和再利用:关键信息。
IF 3.8 3区 生物学 Q1 BIOCHEMICAL RESEARCH METHODS Pub Date : 2022-07-01 Epub Date: 2022-12-26 DOI: 10.1080/14789450.2022.2160324
Yasset Perez-Riverol

Introduction: The creation of ProteomeXchange data workflows in 2012 transformed the field of proteomics, consisting of the standardization of data submission and dissemination and enabling the widespread reanalysis of public MS proteomics data worldwide. ProteomeXchange has triggered a growing trend toward public dissemination of proteomics data, facilitating the assessment, reuse, comparative analyses, and extraction of new findings from public datasets. By 2022, the consortium is integrated by PRIDE, PeptideAtlas, MassIVE, jPOST, iProX, and Panorama Public.

Areas covered: Here, we review and discuss the current ecosystem of resources, guidelines, and file formats for proteomics data dissemination and reanalysis. Special attention is drawn to new exciting quantitative and post-translational modification-oriented resources. The challenges and future directions on data depositions including the lack of metadata and cloud-based and high-performance software solutions for fast and reproducible reanalysis of the available data are discussed.

Expert opinion: The success of ProteomeXchange and the amount of proteomics data available in the public domain have triggered the creation and/or growth of other protein knowledgebase resources. Data reuse is a leading, active, and evolving field; supporting the creation of new formats, tools, and workflows to rediscover and reshape the public proteomics data.

简介2012年,ProteomeXchange数据工作流的创建改变了蛋白质组学领域,包括数据提交和传播的标准化,以及全球范围内公共质谱蛋白质组学数据的广泛再分析。ProteomeXchange 引发了蛋白质组学数据公开传播的趋势,促进了公共数据集的评估、再利用、比较分析和新发现的提取。到 2022 年,该联盟将由 PRIDE、PeptideAtlas、MassIVE、jPOST、iProX 和 Panorama Public 整合而成:在此,我们回顾并讨论了当前用于蛋白质组学数据传播和再分析的资源、指南和文件格式生态系统。我们将特别关注以定量和翻译后修饰为导向的新资源。此外,还讨论了数据沉积所面临的挑战和未来发展方向,包括缺乏元数据和基于云的高性能软件解决方案,无法对现有数据进行快速、可重现的再分析:ProteomeXchange 的成功以及公共领域中可获得的大量蛋白质组学数据引发了其他蛋白质知识库资源的创建和/或增长。数据再利用是一个领先、活跃和不断发展的领域;它支持创建新的格式、工具和工作流程,以重新发现和重塑公共蛋白质组学数据。
{"title":"Proteomic repository data submission, dissemination, and reuse: key messages.","authors":"Yasset Perez-Riverol","doi":"10.1080/14789450.2022.2160324","DOIUrl":"10.1080/14789450.2022.2160324","url":null,"abstract":"<p><strong>Introduction: </strong>The creation of ProteomeXchange data workflows in 2012 transformed the field of proteomics, consisting of the standardization of data submission and dissemination and enabling the widespread reanalysis of public MS proteomics data worldwide. ProteomeXchange has triggered a growing trend toward public dissemination of proteomics data, facilitating the assessment, reuse, comparative analyses, and extraction of new findings from public datasets. By 2022, the consortium is integrated by PRIDE, PeptideAtlas, MassIVE, jPOST, iProX, and Panorama Public.</p><p><strong>Areas covered: </strong>Here, we review and discuss the current ecosystem of resources, guidelines, and file formats for proteomics data dissemination and reanalysis. Special attention is drawn to new exciting quantitative and post-translational modification-oriented resources. The challenges and future directions on data depositions including the lack of metadata and cloud-based and high-performance software solutions for fast and reproducible reanalysis of the available data are discussed.</p><p><strong>Expert opinion: </strong>The success of ProteomeXchange and the amount of proteomics data available in the public domain have triggered the creation and/or growth of other protein knowledgebase resources. Data reuse is a leading, active, and evolving field; supporting the creation of new formats, tools, and workflows to rediscover and reshape the public proteomics data.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"19 7-12","pages":"297-310"},"PeriodicalIF":3.8,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614296/pdf/EMS159053.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9174208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proteomic study of mesothelial and endothelial cross-talk: key lessons. 间皮细胞和内皮细胞串扰的蛋白质组学研究:关键教训。
IF 3.4 3区 生物学 Q1 BIOCHEMICAL RESEARCH METHODS Pub Date : 2022-07-01 DOI: 10.1080/14789450.2023.2174851
Juan Manuel Sacnun, Rebecca Herzog, Klaus Kratochwill

Introduction: The peritoneum, pleura, and pericardium are yet understudied multicellular systems where mesothelial cells (MCs) and endothelial cells (ECs) are in close proximity. Crosstalk between these cell types likely plays role in molecular transport, immunological reactions, and metabolic processes in health, disease, and therapeutic intervention.

Areas covered: In this review, we discuss recent proteomic efforts to characterize the crosstalk between MC and EC. We describe the proteomic methods necessary for investigation of crosstalk between MC and EC, as well as the in-vitro models that can be employed. Potential experimental approaches range from conditioned medium, via co-culture on semi-permeable membranes, to 3D cell culture based organoid models. While the biological and clinical relevance of the models may increase with their ability to mimic close cell communication, the practicality of these complex experiments corresponds vice versa, making standardization more difficult and expensive.

Expert opinion: Currently, data and reports on mesothelial-to-endothelial crosstalk are still very scarce. In our opinion, the in-vitro model using semi-permeable cell culture inserts will allow to establish a basic understanding of cellular crosstalk that may occur between those cell types. Later-on, more sophisticated 3D cell cultures may be better able to simulate the transport dynamics within the peritoneal membrane.

腹膜、胸膜和心包膜是间皮细胞(MCs)和内皮细胞(ECs)距离很近的多细胞系统。这些细胞类型之间的串扰可能在分子运输、免疫反应和健康、疾病和治疗干预中的代谢过程中发挥作用。涵盖的领域:在这篇综述中,我们讨论了最近的蛋白质组学研究,以表征MC和EC之间的串扰。我们描述了研究MC和EC之间串扰所必需的蛋白质组学方法,以及可以使用的体外模型。潜在的实验方法范围从条件培养基,通过在半透膜上共同培养,到基于类器官模型的3D细胞培养。虽然这些模型的生物学和临床相关性可能会随着它们模拟近距离细胞通信的能力而增加,但这些复杂实验的实用性则相反,这使得标准化变得更加困难和昂贵。专家意见:目前,关于间皮-内皮间质串扰的数据和报道仍然非常少。在我们看来,使用半透性细胞培养插入物的体外模型将允许建立对这些细胞类型之间可能发生的细胞串扰的基本理解。随后,更复杂的3D细胞培养可能能够更好地模拟腹膜内的运输动力学。
{"title":"Proteomic study of mesothelial and endothelial cross-talk: key lessons.","authors":"Juan Manuel Sacnun,&nbsp;Rebecca Herzog,&nbsp;Klaus Kratochwill","doi":"10.1080/14789450.2023.2174851","DOIUrl":"https://doi.org/10.1080/14789450.2023.2174851","url":null,"abstract":"<p><strong>Introduction: </strong>The peritoneum, pleura, and pericardium are yet understudied multicellular systems where mesothelial cells (MCs) and endothelial cells (ECs) are in close proximity. Crosstalk between these cell types likely plays role in molecular transport, immunological reactions, and metabolic processes in health, disease, and therapeutic intervention.</p><p><strong>Areas covered: </strong>In this review, we discuss recent proteomic efforts to characterize the crosstalk between MC and EC. We describe the proteomic methods necessary for investigation of crosstalk between MC and EC, as well as the in-vitro models that can be employed. Potential experimental approaches range from conditioned medium, via co-culture on semi-permeable membranes, to 3D cell culture based organoid models. While the biological and clinical relevance of the models may increase with their ability to mimic close cell communication, the practicality of these complex experiments corresponds vice versa, making standardization more difficult and expensive.</p><p><strong>Expert opinion: </strong>Currently, data and reports on mesothelial-to-endothelial crosstalk are still very scarce. In our opinion, the in-vitro model using semi-permeable cell culture inserts will allow to establish a basic understanding of cellular crosstalk that may occur between those cell types. Later-on, more sophisticated 3D cell cultures may be better able to simulate the transport dynamics within the peritoneal membrane.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"19 7-12","pages":"289-296"},"PeriodicalIF":3.4,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9488427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rebellion of the deregulated regulators: What is the clinical relevance of studying intrinsically disordered proteins? 解除管制的监管者的反叛:研究内在无序蛋白质的临床相关性是什么?
IF 3.4 3区 生物学 Q1 BIOCHEMICAL RESEARCH METHODS Pub Date : 2022-07-01 DOI: 10.1080/14789450.2023.2176755
Vladimir N Uversky
Since at the molecular level, almost all physiological processes are defined by the specific activities of specific proteins or protein groups, dysfunction and deregulation of these proteins are linked to the pathogenesis of various maladies. Therefore, to get to the roots of the pathological processes and find appropriate cure for the related diseases, one should clearly know the connections between protein-centric physiology and pathology. This logic represents premises of the medical protein science, where one is looking for the connections between the ‘right’ protein structure and normal function to understand how dysfunction can be linked back to the ‘wrong’ structure and assuming that fixing such ‘wrong’ structure can serve as a means to restore a normal function and therefore cure a disease. Even though mutations in a gene encoding a culprit protein represent the major reason for this protein to gain ‘wrong’ structure, dysfunctionality can also be caused by the distortion of any means from a very broad arsenal of cellular proteostasis-related mechanisms evolved to control and regulate protein folding, structure, and function. Although for the first time, proteins were described by the Dutch chemist Gerardus Johannes Mulder (1802–1880) as enormous molecules, with empirical formula for fibrin and egg albumin being C400H620N100O120P1S1, in his 1838 paper ‘On the composition of some animal substances’ first published in French [1] and translated to German in 1839 [2], they gained serious attention of researchers only after their polypeptide nature discovered independently in 1902 by a German chemist Hermann Emil Louis Fischer (1852–1919) [3] and an early protein scientist Franz Hofmeister (1850–1922) [4] was connected to the enzymatic activity by an American chemist, James B. Sumner (1887–1955), who, in 1926, showed that the enzyme urease is a protein that can be isolated and crystallized [5]. Curiously, as early as in 1894, enzymatic activity was proposed by Emil Fischer to follow his classical ‘lock-and-key’ model [6]. This concept was eventually elaborated into the famous protein structure-function paradigm, where the amino acid sequence determines a uniquely folded 3D structure that can be visualized in the crystalline state and that, in turn, defines the unique protein function [7]. As a result, in most of the almost 185 years of their history (and definitely since 1894), proteins were equated to enzymes, being considered as biological catalysts, while many other functions of these biological macromolecules and their intriguing potential to be multifunctional were mostly ignored.
{"title":"Rebellion of the deregulated regulators: What is the clinical relevance of studying intrinsically disordered proteins?","authors":"Vladimir N Uversky","doi":"10.1080/14789450.2023.2176755","DOIUrl":"https://doi.org/10.1080/14789450.2023.2176755","url":null,"abstract":"Since at the molecular level, almost all physiological processes are defined by the specific activities of specific proteins or protein groups, dysfunction and deregulation of these proteins are linked to the pathogenesis of various maladies. Therefore, to get to the roots of the pathological processes and find appropriate cure for the related diseases, one should clearly know the connections between protein-centric physiology and pathology. This logic represents premises of the medical protein science, where one is looking for the connections between the ‘right’ protein structure and normal function to understand how dysfunction can be linked back to the ‘wrong’ structure and assuming that fixing such ‘wrong’ structure can serve as a means to restore a normal function and therefore cure a disease. Even though mutations in a gene encoding a culprit protein represent the major reason for this protein to gain ‘wrong’ structure, dysfunctionality can also be caused by the distortion of any means from a very broad arsenal of cellular proteostasis-related mechanisms evolved to control and regulate protein folding, structure, and function. Although for the first time, proteins were described by the Dutch chemist Gerardus Johannes Mulder (1802–1880) as enormous molecules, with empirical formula for fibrin and egg albumin being C400H620N100O120P1S1, in his 1838 paper ‘On the composition of some animal substances’ first published in French [1] and translated to German in 1839 [2], they gained serious attention of researchers only after their polypeptide nature discovered independently in 1902 by a German chemist Hermann Emil Louis Fischer (1852–1919) [3] and an early protein scientist Franz Hofmeister (1850–1922) [4] was connected to the enzymatic activity by an American chemist, James B. Sumner (1887–1955), who, in 1926, showed that the enzyme urease is a protein that can be isolated and crystallized [5]. Curiously, as early as in 1894, enzymatic activity was proposed by Emil Fischer to follow his classical ‘lock-and-key’ model [6]. This concept was eventually elaborated into the famous protein structure-function paradigm, where the amino acid sequence determines a uniquely folded 3D structure that can be visualized in the crystalline state and that, in turn, defines the unique protein function [7]. As a result, in most of the almost 185 years of their history (and definitely since 1894), proteins were equated to enzymes, being considered as biological catalysts, while many other functions of these biological macromolecules and their intriguing potential to be multifunctional were mostly ignored.","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"19 7-12","pages":"279-282"},"PeriodicalIF":3.4,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9120103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Advances in phosphoproteomics and its application to COPD. 磷酸蛋白质组学研究进展及其在COPD中的应用。
IF 3.4 3区 生物学 Q1 BIOCHEMICAL RESEARCH METHODS Pub Date : 2022-07-01 DOI: 10.1080/14789450.2023.2176756
Xiaoyin Zeng, Yanting Lan, Jing Xiao, Longbo Hu, Long Tan, Mengdi Liang, Xufei Wang, Shaohua Lu, Tao Peng, Fei Long

Introduction: Chronic obstructive pulmonary disease (COPD) was the third leading cause of global death in 2019, causing a huge economic burden to society. Therefore, it is urgent to identify specific phenotypes of COPD patients through early detection, and to promptly treat exacerbations. The field of phosphoproteomics has been a massive advancement, compelled by the developments in mass spectrometry, enrichment strategies, algorithms, and tools. Modern mass spectrometry-based phosphoproteomics allows understanding of disease pathobiology, biomarker discovery, and predicting new therapeutic modalities.

Areas covered: In this article, we present an overview of phosphoproteomic research and strategies for enrichment and fractionation of phosphopeptides, identification of phosphorylation sites, chromatographic separation and mass spectrometry detection strategies, and the potential application of phosphorylated proteomic analysis in the diagnosis, treatment, and prognosis of COPD disease.

Expert opinion: The role of phosphoproteomics in COPD is critical for understanding disease pathobiology, identifying potential biomarkers, and predicting new therapeutic approaches. However, the complexity of COPD requires the more comprehensive understanding that can be achieved through integrated multi-omics studies. Phosphoproteomics, as a part of these multi-omics approaches, can provide valuable insights into the underlying mechanisms of COPD.

慢性阻塞性肺疾病(COPD)是2019年全球第三大死亡原因,给社会造成了巨大的经济负担。因此,通过早期发现来识别COPD患者的特定表型,并及时治疗加重是当务之急。由于质谱、富集策略、算法和工具的发展,磷酸化蛋白质组学领域已经取得了巨大的进步。以现代质谱为基础的磷蛋白质组学可以理解疾病的病理生物学、生物标志物的发现和预测新的治疗方式。涉及领域:在这篇文章中,我们概述了磷酸化蛋白质组学的研究和磷酸化肽的富集和分离策略,磷酸化位点的鉴定,色谱分离和质谱检测策略,以及磷酸化蛋白质组学分析在COPD疾病的诊断、治疗和预后中的潜在应用。专家意见:磷蛋白组学在COPD中的作用对于理解疾病病理生物学、识别潜在的生物标志物和预测新的治疗方法至关重要。然而,COPD的复杂性需要更全面的了解,这可以通过综合多组学研究来实现。磷蛋白组学作为这些多组学方法的一部分,可以为COPD的潜在机制提供有价值的见解。
{"title":"Advances in phosphoproteomics and its application to COPD.","authors":"Xiaoyin Zeng,&nbsp;Yanting Lan,&nbsp;Jing Xiao,&nbsp;Longbo Hu,&nbsp;Long Tan,&nbsp;Mengdi Liang,&nbsp;Xufei Wang,&nbsp;Shaohua Lu,&nbsp;Tao Peng,&nbsp;Fei Long","doi":"10.1080/14789450.2023.2176756","DOIUrl":"https://doi.org/10.1080/14789450.2023.2176756","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic obstructive pulmonary disease (COPD) was the third leading cause of global death in 2019, causing a huge economic burden to society. Therefore, it is urgent to identify specific phenotypes of COPD patients through early detection, and to promptly treat exacerbations. The field of phosphoproteomics has been a massive advancement, compelled by the developments in mass spectrometry, enrichment strategies, algorithms, and tools. Modern mass spectrometry-based phosphoproteomics allows understanding of disease pathobiology, biomarker discovery, and predicting new therapeutic modalities.</p><p><strong>Areas covered: </strong>In this article, we present an overview of phosphoproteomic research and strategies for enrichment and fractionation of phosphopeptides, identification of phosphorylation sites, chromatographic separation and mass spectrometry detection strategies, and the potential application of phosphorylated proteomic analysis in the diagnosis, treatment, and prognosis of COPD disease.</p><p><strong>Expert opinion: </strong>The role of phosphoproteomics in COPD is critical for understanding disease pathobiology, identifying potential biomarkers, and predicting new therapeutic approaches. However, the complexity of COPD requires the more comprehensive understanding that can be achieved through integrated multi-omics studies. Phosphoproteomics, as a part of these multi-omics approaches, can provide valuable insights into the underlying mechanisms of COPD.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"19 7-12","pages":"311-324"},"PeriodicalIF":3.4,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9118955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Expert Review of Proteomics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1